Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:48 PM
Ignite Modification Date:
2025-12-24 @ 10:48 PM
NCT ID:
NCT03140969
Eligibility Criteria:
Inclusion Criteria:
* Male or female, ≥ 6 years of age at Screening with a clinical diagnosis of LCA and a molecular diagnosis of homozygosity or compound heterozygosity for the CEP290 p.Cys998X mutation.
* Best-corrected visual acuity greater than or equal to light perception in both eyes and equal to or worse than LogMAR +1.0 (Snellen notation 20/200) in the worse eye and equal to or worse than LogMAR +0.7 (Snellen notation 20/100) in the contralateral eye.
* Detectable outer nuclear layer (ONL) in the area of the macula.
* An electroretinogram (ERG) result consistent with LCA.
* Clear ocular media and adequate pupillary dilation to permit good quality retinal imaging.
Exclusion Criteria:
* Syndromic disease.
* Pregnant or breast-feeding female.
* Any clinically significant cardiac disease or defect.
* One or more coagulation parameters outside of the normal range.
* Any ocular disease or condition that could compromise treatment safety, visual acuity or interfere with assessment of efficacy and safety.
* Prior receipt of intraocular surgery or intravitreal injection within 3 months prior to study start or planned intraocular surgery or procedure during the course of the study.
* Use of any investigational drug or device within 90 days or 5 half-lives of Day 1, whichever is longer, or plans to participate in another study of a drug or device during the PQ-110-001 study period.
* Any prior receipt of genetic therapy for LCA
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
6 Years
Study:
NCT03140969
Study Brief:
Protocol Section:
NCT03140969